News
BMRA
3.080
+0.98%
0.030
Biomerica to Participate at BTIG Biotech Conference
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August...
GlobeNewswire · 2d ago
Biomerica gets EU's CE mark for its diagnostic test to detect H. pylori bacteria
Biomerica (NASDAQ:BMRA) on Thursday said it got the European Commission's CE Mark for its hp+detect diagnostic test that detects the bacteria Helicobacter pylori. BMRA stock -0.2% to $2.78 in premarket trade. The CE
Seekingalpha · 05/12 13:02
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen, mean...
GlobeNewswire · 05/12 12:19
Biomerica Says H Pylori Diagnostic Test Receives CE Mark
MT Newswires · 05/12 10:55
Biomerica stock rises on filing with FDA to market bacteria detection test
Biomerica (NASDAQ:BMRA) submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for hp+detect test that detects the presence of Helicobacter pylori (H. pylori) bacteria. The company said that over
Seekingalpha · 04/26 13:15
BRIEF-Biomerica Reports FDA Submission For Test to Detect H. pylori
reuters.com · 04/26 12:21
Biomerica Reports FDA Submission For Test To Detect Helicobacter Pylori
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic
Benzinga · 04/26 12:19
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., April 26, 2022 (GL...
GlobeNewswire · 04/26 12:19
Biomerica Seeks FDA Clearance for Bacteria-Detecting Device
MT Newswires · 04/26 10:54
Biomerica: Q3 Earnings Insights
Biomerica (NASDAQ:BMRA) reported its Q3 earnings results on Thursday, April 14, 2022 at 08:31 AM. Here's what investors need to know about the announcement. Earnings Biomerica beat estimated earnings by 90.0%, reporting an EPS of $-0.01 versus an estimate ...
Benzinga · 04/14 20:41
Biomerica GAAP EPS of -$0.01, revenue of $7.6M
Biomerica press release (NASDAQ:BMRA): Q3 GAAP EPS of -$0.01. Revenue of $7.6M (+111.1% Y/Y).
Seekingalpha · 04/14 12:57
Biomerica Q3 EPS $(0.01) Up From $(0.18) YoY, Sales $7.60M Up From $3.63M YoY
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.01) per share. This is a 94.44 percent increase over losses of $(0.18) per share from the same period last year. The company reported $7.60 million in sales this
Benzinga · 04/14 12:38
Biomerica Posts Encouraging Results From InFoods Study As Irritable Bowel Syndrome Treatment
Biomerica Inc (NASDAQ: BMRA) has 
Benzinga · 02/08 17:27
BRIEF-Biomerica Announces Positive Topline Results From Endpoint Clinical Trial Of Its Infoods IBS Treatment
reuters.com · 02/08 12:27
Biomerica rises 9% on positive data in InFoods IBS study for irritable bowel syndrome
Biomerica (NASDAQ:BMRA) reported positive results from trial of its test, InFoods IBS diagnostic-guided therapy (DGT) in patients with Irritable Bowel Syndrome (IBS). The InFoods DGT for IBS uses a simple blood
Seekingalpha · 02/08 12:21
Biomerica Announces Topline Results From The Endpoint Clinical Trial Of Its InFoods IBS Treatment For Patients With Irritable Bowel Syndrome; Co. Reported 'Multiple endpoints demonstrated statistically significant improvements'
  InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS
Benzinga · 02/08 11:47
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugsMultiple endpoints demonstrated st...
GlobeNewswire · 02/08 11:39
Top Premarket Gainers
MT Newswires · 01/27 08:14
Biomerica's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q2, Biomerica's (NASDAQ:BMRA) reported sales totaled $4.65 million. Despite a 27.05% increase in earnings, the company posted a loss of $1.13 million.
Benzinga · 01/13 14:55
Biomerica reports FQ2 results
Biomerica press release (NASDAQ:BMRA): FQ2 Revenue of $4.6M (+228.6% Y/Y). Net loss decreased to $1.1M for the three months ended November 30, 2021 compared to a net loss of $1.7M
Seekingalpha · 01/13 13:44
More
Webull provides a variety of real-time BMRA stock news. You can receive the latest news about Biomerica Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRA
Biomerica, Inc., (Biomerica) is a biomedical technology company. The Company develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The Company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The Company is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.